Lynparza approved by NICE UK for first-line maintenance treatment for BRCAm ovarian cancer

NICE's decision is based on the results of the critical Phase III clinical study SOLO-1The results showed that Lynparza achieved a statistically significant and clinically significant improvement in progressionless (PFS) compared to placebo, reduced the risk of disease progression or death by 70% (HR?0.30.30.25%CI-0.23-0.41), p.001)After 41 months of follow-up, the pfS in the Lynparza treatment group did not reach, and the placebo group was 13.8 monthsIn the Lynparza treatment group, 60.4 percent of patients did not progress after three years of treatment, compared with 26.9 percent in the placebo groupIn this study, Lynparza's safety characteristics were consistent with previous studiesDr Susana Banerjee, consultant physician in oncology at the royal Marsdenand head of the ICR Gynaecological Cancer Group and co-investigator of the SOLO-1 research team, said: "Lynparza maintenance therapy heralds a new era for ovarian cancer patientsThis is the first time we have seen such a significant improvement in progress-free survivalThe iconic clinical trial SOLO-1 has transformed the treatment model for women with advanced ovarian cancerResults to date have shown that Lynparza maintenance therapy extended the progression-free survival of patients with brcAm advanced ovarian cancer by about three yearsLynparza is a pioneering oral PARP inhibitor that prioritizes the use of defects in DNA repair pathways to kill cancer cells, a mode of action that gives Lynparza the potential to treat a wide range of types of tumors with DNA repair defectsPARP is associated with a wide range of tumor types, especially breast and ovarian cancerLynparza, the world's first PARP inhibitor, was first approved by the U.SFDA in December 2014 for advanced ovarian cancer patients with harmful or suspected harmful type BRCA mutations (gBRCAm)To date, the drug has also been approved by more than 60 countries around the world to maintain the treatment of platinum-sensitive recurrent ovarian cancer ( regardless of BRCA status)In addition, the drug has been approved by the United States, Canada, Japan, Australia, for the previous chemotherapy has been undergoing the type of BRCA mutation HER2 negative metastatic breast cancer, in the European Union this indication includes localized advanced breast cancer patientsAstraZeneca and Mersadon reached a global partnership for oncology in July 2017 to jointly develop and commercialize Lynparza and another MEK inhibitor, selumetinib, for the treatment of a wide range of tumorsCurrently, the two sides are conducting several clinical studies to investigate the potential of Lynparza for a wide range of types of tumors, including breast, prostate and pancreatic cancersIn the area of ovarian cancer, the two sides are advancing a number of studies, including the ongoing GINECO/ENGOTov25 III study paOLA-1, which is testing Lynparza in conjunction with Roche Amvetin (Avastin, Bevala monoantigen) as a first-line maintenance treatment for patients with advanced (FIGO phase iii: phase III and IV) ovarian cancer, regardless of their BRCA status, the results are expected to be published in the second half of 2019in the Chinese market, Lynparza was approved by China's National Drug Administration (CNDA) on August 23, 2018 for the maintenance of platinum-sensitive recurrent ovarian cancerThe approval, making Lynparza the first targeted drug approved in the Chinese market to treat ovarian cancer, marks the beginning of the ERA of PARP inhibitors for ovarian cancer treatment in Chinaoriginal origin: AstraZeneca's Lynparza approved via Cancer Drugs Fund for BRCA plus the canceroriginal title: "BrcAm ovarian cancer major progress! AstraZeneca/Mersa East Lynparza (Lipjo) approved by NICE UK for first-line maintenance treatment